| Bioactivity | PSI (TFA) is a potent proteasome inhibitor. PSI (TFA) inhibits the proliferation of primary effusion lymphoma (PEL) cells. PSI (TFA) can be used for the research of Kaposi’s sarcoma-associated herpesvirus (KSHV) infection and KSHV-associated lymphomas[1]. |
| Target | CC50: 205 nM (BJAB cells); 190 nM (Ramos cells); 22.0 nM (BC3 cells); 53.0 nM (BCBL1 cells) |
| Invitro | PSI (TFA) (24 h) inhibits the proliferation with CC50 values of 205, 190, 22.0, 53.0 nM for BJAB, Ramos, BC3, BCBL1 cells, respectively)[1].PSI (TFA) (50 nM; 6 h) increases caspase-3/7 activity by 8-fold compared with control[1].PSI (TFA) (50 nM; 6 h) decreases the transcriptional activity of NF-κB by 52%[1].PSI (TFA) (1, 5 nM; 3 days) inhibits the growth of BC3 cells at a high concentration (5 nM)[1]. Cell Cytotoxicity Assay[1] Cell Line: |
| Name | PSI TFA |
| Formula | C34H51F3N4O10 |
| Molar Mass | 732.78 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Saji C, et al. Proteasome inhibitors induce apoptosis and reduce viral replication in primary effusion lymphoma cells. Biochem Biophys Res Commun. 2011; 415(4):573-8. |